BMO Capital Rates Incyte (INCY) hold, $94 Price Target
BMO Capital raises Incyte Corporation's rating to hold with a $94 price target, a 13.33% downside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BMO Capital rated Incyte Corporation ($INCY) "hold" with a $94 price target on June 22, 2026.
Since the rating, $INCY is up 10.6% after 1 week, up 11.7% after 1 month and up 9.1% to date (from the $103.66 close on Jun 22, 2026).
INCY
Incyte Corporation
Key Points
- BMO Capital upgraded Incyte Corporation to a hold rating with a $94 price target on June 22, 2026.
- BMO Capital's $94 price target implies 13.33% downside from Incyte Corporation's ($INCY) current $108.46 share price.
- Shares of Incyte Corporation traded near $98.22 on Monday, with a market cap of $19.6 billion and a P/E ratio of 13.89.
- Insiders recently bought shares, and analysts have varied ratings with a consensus target of $109.35.
Get $INCY trade alerts by text
We text you when insiders, Congress or big funds trade $INCY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Incyte Corporation alert may contain errors. Disclosures
BMO Capital has upgraded Incyte Corporation (NasdaqGS: INCY) to a hold rating, setting a price target of $94. Analyst Evan Seigerman announced the change on June 22, 2026. This adjustment comes as the stock traded near $98.22 on Monday.
BMO Capital vs. the S&P 500
Hypothetical returns from BMO Capital's disclosed trades, not real profit or advice. How we model this.
Incyte Corporation Stock Down 13.4%
Shares of Incyte Corporation traded around $98.22 on Monday. The company, valued at approximately $19.6 billion, has a P/E ratio of 13.89 and a forward P/E of 10.72. With a beta of 0.79, Incyte's stock has experienced a 52-week low of $66.74 and a high of $112.29. The stock's 50-day moving average is $98.17, while its 200-day moving average is $96.80. Incyte maintains a strong liquidity position with a current ratio of 3.68 and a quick ratio of 3.40, alongside a debt-to-equity ratio of 0.70.
$INCY price target
Incyte Corporation daily closes and this analyst's $94 target. Not advice.
Recent Earnings
Incyte reported revenue of approximately $5.36 billion, reflecting a growth of 20.9%. The company's net margin stands at 26.7%, with a return on equity of 30.8%. Earnings per share (EPS) is reported at $7.07. Incyte's next earnings date is scheduled for July 28, 2026.
Insider Buying and Selling at Incyte Corporation
Several insiders at Incyte Corporation recently bought shares on June 8, 2026. Otis Brawley, Edmund Harrigan, Paul Clancy, Katherine High, and Jacqualyn Fouse each purchased shares, with Brawley and High acquiring 6,111 shares each. These transactions were not part of a planned trading program.
Analysts Set New Price Targets
On June 22, 2026, BMO Capital upgraded Incyte to a hold rating with a $94 price target. HC Wainwright & Co. maintained its buy rating with a $140 target on June 9, 2026, while Bernstein initiated coverage with a hold rating and a $99 target on May 22, 2026. Overall, 23 analysts have a consensus recommendation of 'buy' with a mean target price of $109.35.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company based in Wilmington, Delaware. It focuses on discovering, developing, and commercializing therapeutics, primarily in oncology, across the United States, Europe, Canada, and Japan. The company is known for its products like Jakafi and Iclusig, used in treating various cancers and other severe conditions. Incyte collaborates with major firms like Novartis and Lilly and has a strong research and development pipeline. It was incorporated in 1991 and employs about 2,844 people under the leadership of CEO William J. Meury.
Bottom Line
Incyte Corporation's stock has seen varied analyst opinions, with BMO Capital recently upgrading it to a hold rating. The company's strong financial position and active insider buying may be of interest to investors. However, it's important to remember that analyst ratings and insider activities are just part of the broader investment landscape.
Related Filing Alerts
Source: BMO Capital's rating change on $INCY (Jun 22, 2026). Written by software, not financial advice. How we make alerts